Department of Medical Oncology, St James's Institute of Oncology, Beckett Street, Leeds, UK.
J Clin Pathol. 2012 Jul;65(7):580-4. doi: 10.1136/jclinpath-2011-200320. Epub 2011 Oct 19.
Mucinous epithelial ovarian cancers (mEOC) are a relatively rare subset of ovarian cancers. Despite a relatively favourable outcome in early disease, the more frequent advanced presentation is associated with poorer response to platinum/taxane chemotherapies, and poorer survival, compared to serous ovarian cancers. We consider some of the fundamental clinico-pathological and molecular features, and existing clinical trial data regarding mEOC. Underlying molecular differences, between mEOC and serous cancers may contribute to the observed clinical differences, including an increased prevalence of K-RAS mutations in mEOC, more in keeping with gastrointestinal tumours. This observation contributes to the rationale for a trial ("mEOC") investigating the use of "ovarian" versus "gastrointestinal" style chemotherapy. Looking to potential future approaches, we speculate upon the potential impact of emerging technologies on the future investigation and management of mEOC.
黏液性卵巢上皮癌（mEOC）是一种相对罕见的卵巢癌亚型。尽管在早期疾病中预后相对较好，但与浆液性卵巢癌相比，更常见的晚期表现与对铂类/紫杉醇化疗的反应较差和生存率较低相关。我们考虑了一些基本的临床病理和分子特征，以及关于 mEOC 的现有临床试验数据。mEOC 和浆液性癌症之间的潜在分子差异可能导致观察到的临床差异，包括 mEOC 中 K-RAS 突变的发生率增加，更符合胃肠道肿瘤。这一观察结果为一项临床试验（“mEOC”）提供了依据，该试验旨在研究使用“卵巢”与“胃肠道”式化疗的效果。展望未来的潜在方法，我们推测新兴技术对 mEOC 的未来研究和管理的潜在影响。
